Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 7/20 | 0.35 |
| ▸ | MAOA | P21397 | 6/20 | 0.35 |
| ▸ | MAOB | P27338 | 6/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860484 | 0.72 | KMT2A (0.40) | EPHX1KDM1AMAOAMAOBPOLB | |
| SCHEMBL5862723 | 0.72 | KMT2A (0.40) | EPHX1KDM1AMAOAMAOBPOLB | |
| SCHEMBL329169 | 0.72 | KMT2A (0.40) | EPHX1KDM1AMAOAMAOBPOLB | |
| SCHEMBL6926219 | 0.71 | PDE1C (0.47) | POLB | |
| SCHEMBL6926221 | 0.71 | PDE1C (0.47) | POLB | |
| SCHEMBL9257647 | 0.71 | PTGS2 (0.38) | EPHX1EDNRAKMT2ANPSR1L3MBTL1 | |
| SCHEMBL8108217 | 0.71 | PTGS2 (0.38) | EPHX1EDNRAKMT2ANPSR1L3MBTL1 | |
| SCHEMBL8993499 | 0.71 | PTGS2 (0.38) | EPHX1EDNRAKMT2ANPSR1L3MBTL1 | |
| SCHEMBL273608 | 0.68 | TSHR (0.39) | KDM1AMAOAMAOBPOLBKMT2A | |
| SCHEMBL8876521 | 0.68 | TSHR (0.39) | KDM1AMAOAMAOBPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412319-A1 | CHIRAL RESOLUTION METHOD FOR PRODUCING COMPOUNDS USEFUL IN THE SYNTHESIS OF TAXANES | NAPRO BIOTHERAPEUTICS, INC. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6653501-B2 | Using chromatographic process for separating a target chiral compound from its enantiomer in a racemic mixtures; purification | NAPRO BIOTHERAPEUTICS, INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030045743-A1 | Chiral resolution method for producing compounds useful in the synthesis of taxanes | MAYNE PHARMA (USA), INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2003002509-A1 | CHIRAL RESOLUTION METHOD FOR PRODUCING COMPOUNDS USEFUL IN THE SYNTHESIS OF TAXANES | NAPRO BIOTHERAPEUTICS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045743-A1 | Chiral resolution method for producing compounds useful in the synthesis of taxanes | CCNK, OPRK1, SYMPK | EPHX1 1034/4885KDM1A 4756/4885MAOA 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.